Abbvie (ABBV) Stock
Established biopharmaceutical company with strong cash flow. Here's the price, business snapshot, and what's worth knowing about Abbvie in June 2026.
AbbVie Inc (ABBV) is a large-cap biopharmaceutical company known for established prescription medicines and an expanding pipeline. Historically driven by a few high-revenue products, AbbVie has sought to diversify through R&D, new product launches and acquisitions. The company generates significant free cash flow and is a regular dividend payer, which may attract income-focused investors. Key considerations for potential investors include patent and competition risks (including biosimilars), the outcome of clinical trials, regulatory approvals and pricing pressure in major markets. Market-cap scale and a broad geographic footprint can offer resilience, but revenues can be volatile around patent cliffs and product lifecycle events. This summary is for general educational purposes only and is not personal investment advice; investors should assess their own risk tolerance, time horizon and seek independent advice before acting. Past performance is not a guide to future results.
Why It’s Moving
AbbVie’s stock is holding up as analysts stay broadly constructive, but the real near-term driver is still the latest Wall Street reassessment of its earnings outlook.
- Analyst consensus remains Buy, with multiple recent forecasts pointing to moderate upside and signaling that Wall Street still sees AbbVie’s portfolio as a long-term earnings engine.
- Recent target revisions have been mixed, which keeps the stock from breaking out decisively and reflects a market still debating how much growth is already priced in.
- In the absence of a major earnings or product headline over the past week, ABBV is being pulled by broader healthcare rotation and investor appetite for defensive large-cap pharma names.
AbbVie’s stock is holding up as analysts stay broadly constructive, but the real near-term driver is still the latest Wall Street reassessment of its earnings outlook.
- Analyst consensus remains Buy, with multiple recent forecasts pointing to moderate upside and signaling that Wall Street still sees AbbVie’s portfolio as a long-term earnings engine.
- Recent target revisions have been mixed, which keeps the stock from breaking out decisively and reflects a market still debating how much growth is already priced in.
- In the absence of a major earnings or product headline over the past week, ABBV is being pulled by broader healthcare rotation and investor appetite for defensive large-cap pharma names.
When is the next earnings date for AbbVie (ABBV)?
AbbVie’s next earnings date is expected to be July 30, 2026, based on the company’s historical reporting pattern and current analyst calendars. The report should cover Q2 2026 results. The company has not officially confirmed the date yet, but late July is the most consistently indicated window.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AbbVie's stock with a target price of $187.99, indicating growth potential.
Financial Health
AbbVie is generating strong revenue and profits, with solid cash flow supporting its operations.
Dividend
AbbVie's average dividend yield of 2.96% offers a reasonable income opportunity for investors seeking dividends. If you invested $1000 you would be paid $29.60 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
AMNEAL PHARMACEUTICALS INC
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
Baskets Featuring ABBV
TYK2 Inhibitors: Might Oral Drugs Rule Autoimmune?
Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
Published: 7 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketCancer Therapies: What's Next After 100% Response Rate
Regeneron's announcement of a 100% response rate for its new lymphoma therapy highlights a major advancement in cancer treatment. This breakthrough creates an investment opportunity centered on companies pioneering next-generation immuno-oncology drugs, particularly those developing bispecific antibodies and other innovative platforms.
Published: 7 December 2025
Explore BasketRinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published: 21 October 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: 1 August 2025
Explore BasketPharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: 31 July 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: 3 July 2025
Explore BasketMarket Indecision
Find refuge from market volatility with these carefully selected companies providing essential goods and services. Our professional analysts have handpicked high-quality, dividend-paying stocks in defensive sectors that offer stability when economic futures look uncertain.
Published: 18 June 2025
Explore BasketEmpire Builders
These companies are led by visionaries who excel at growing through smart acquisitions. Our analysts have carefully selected businesses with proven ability to buy competitors, integrate them successfully, and build lasting market power.
Published: 17 June 2025
Explore BasketMind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: 17 June 2025
Explore BasketLow Volatility Stocks
Are you feeling seasick? Sail through calmer waters with these lower volatility investments. These handpicked stocks were carefully selected by our analysts for their history of stability and potential for consistent returns over time.
Published: 21 May 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: 6 May 2025
Explore BasketTop Dividend Paying Stocks
These reliable companies have a proven track record of sharing profits with investors through regular dividend payments. Carefully selected by our professional analysts, these stocks offer the potential for both steady income and long-term growth.
Published: 3 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Large-cap pharma value
Generates strong cash flows and has a track record of dividends, which may suit income-oriented allocations — though yields and share performance can fluctuate.
Pipeline and innovation
New drug approvals and successful trials can drive growth, but R&D outcomes are uncertain and clinical setbacks are possible.
Global market exposure
A broad geographic footprint diversifies revenue sources, while differing regulations and pricing environments create both opportunity and risk.
Compare AbbVie with other stocks
AbbVie vs Bristol Myers Squibb
AbbVie vs Bristol Myers Squibb: Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
